Physician profile
Jeffrey D Dodd
NPI 1861444176
$24,061.65
in general payments reported to CMS, 2019-2025
64 companies · $3,531 in 2025
The $3,531 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,758 · 2020: $3,059 · 2021: $3,739 · 2022: $2,909 · 2023: $3,889 · 2024: $4,177 · 2025: $3,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,572.05 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,839.47 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $2,681.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,519.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,300.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,215.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sunovion Pharmaceuticals INC. | $950.30 | 2019-2022 | |
| Corium, LLC | $938.02 | 2022-2024 | Azstarys, Azstarys |
| Amarin Pharma, INC. | $932.45 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $808.23 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $758.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $693.65 | 2022-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $678.69 | 2019-2025 | |
| Alkermes, INC. | $662.70 | 2022-2025 | Aristada, Lybalvi |
| Amgen INC. | $602.32 | 2020-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $568.26 | 2019-2025 | Xifaxan, Trulance |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $557.33 | 2019-2020 | |
| Astellas Pharma US INC | $433.53 | 2019-2024 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $346.86 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $339.35 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $330.53 | 2023-2025 | |
| Lundbeck LLC | $328.62 | 2020-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $323.53 | 2024-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $300.27 | 2019-2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $237.38 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $230.97 | 2020-2021 | |
| Antares Pharma, INC. | $229.42 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Indivior INC. | $229.24 | 2019-2025 | Sublocade |
| Sumitomo Pharma America, INC. | $218.23 | 2023-2025 | Gemtesa, Aptiom |
| Biohaven Pharmaceutical Holding Company LTD. | $200.56 | 2022 | |
| Merck Sharp & Dohme LLC | $198.56 | 2019-2022 | |
| Tris Pharma INC | $192.74 | 2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Axsome Therapeutics, INC. | $179.49 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $169.42 | 2019-2025 | Ajovy |
| Otsuka America Pharmaceutical, INC. | $168.93 | 2020-2025 | Rexulti |
| Abbott Laboratories | $152.86 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $130.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Urovant Sciences INC | $125.00 | 2022 | |
| Tolmar, INC. | $103.06 | 2024-2025 | Jatenzo |
| Grifols USA, LLC | $102.78 | 2019-2023 | Prolastin-C Liquid |
| Kowa Pharmaceuticals America, INC. | $95.19 | 2020-2023 | Seglentis |
| Clarus Therapeutics INC. | $93.38 | 2021 | |
| Endo Pharmaceuticals INC. | $79.09 | 2020-2022 | |
| Mylan Specialty L.P. | $78.61 | 2021-2024 | Yupelri |
| Supernus Pharmaceuticals, INC. | $76.02 | 2020-2022 | Xyosted, Tlando |
| Novartis Pharmaceuticals Corporation | $74.42 | 2021-2024 | |
| Sanofi Pasteur INC. | $68.06 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $58.90 | 2022-2023 | Ingrezza |
| Currax Pharmaceuticals LLC | $53.61 | 2021-2023 | Nexletol |
| Ardelyx, INC. | $48.50 | 2024 | Ibsrela |
| Viatris Specialty LLC | $45.76 | 2025 | Yupelri |
| Kaleo, INC. | $38.74 | 2019-2021 | |
| Verona Pharma, INC. | $33.82 | 2025 | Ohtuvayre |
| Dexcom, INC. | $33.26 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $32.95 | 2023-2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $31.88 | 2019 | |
| Halozyme INC | $18.29 | 2023 | |
| Insulet Corporation | $17.87 | 2021 | |
| Eisai INC. | $17.46 | 2020 | |
| Genentech USA, INC. | $16.69 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.02 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.49 | 2025 | Xhance, Nuzyra |
| Adlon Therapeutics L.P. | $14.28 | 2020 | |
| Amneal Pharmaceuticals LLC | $14.02 | 2025 | Unithroid |
| Rhythm Pharmaceuticals, INC. | $14.01 | 2023 | Imcivree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.